Skip to main content

Table 1 Demographic and clinical characteristics of adolescents and young adults with breast cancer by subtype,a 2005 to 2009

From: Occurrence of breast cancer subtypes in adolescent and young adult women

 

Total

HR+/HER2-a

HR+/HER2+a

HR-/HER2+a

Triple-negativea

Unclassified

 

(N= 5,605)

(n= 2,306)

(n= 843)

(n= 485)

(n= 1,073)

(n= 898)

Characteristics

N

n

Col%

n

Col%

n

Col%

n

Col%

n

Col%

Age group (years)

           

   15-24

97

36

(1.6)

11

(1.3)

12

(2.5)

11

(1.0)

27

(3.0)

   25-29

482

161

(7.0)

81

(9.6)

53

(10.9)

98

(9.1)

89

(9.9)

   30-34

1,507

557

(24.2)

246

(29.2)

144

(29.7)

319

(29.7)

241

(26.8)

   35-39

3,519

1,552

(67.3)

505

(59.9)

276

(56.9)

645

(60.1)

541

(60.2)

Race/ethnicity

           

   White

2,394

1,050

(45.5)

347

(41.2)

198

(40.8)

430

(40.1)

369

(41.1)

   Black

421

135

(5.9)

66

(7.8)

39

(8.0)

117

(10.9)

64

(7.1)

   Hispanic

1,801

678

(29.4)

271

(32.2)

166

(34.2)

394

(36.7)

292

(32.5)

   Asian

917

423

(18.3)

152

(18.0)

79

(16.3)

116

(10.8)

147

(16.4)

   Unknown/other

72

20

(0.9)

7

(0.8)

b

 

16

(1.5)

26

(2.9)

Year of diagnosis

           

   2005

1,134

367

(15.9)

157

(18.6)

101

(20.8)

226

(21.1)

283

(31.5)

   2006

1,133

444

(19.3)

192

(22.8)

106

(21.9)

212

(19.8)

179

(19.9)

   2007

1,074

463

(20.1)

145

(17.2)

100

(20.6)

207

(19.3)

159

(17.7)

   2008

1,205

540

(23.4)

168

(19.9)

103

(21.2)

239

(22.3)

155

(17.3)

   2009

1,059

492

(21.3)

181

(21.5)

75

(15.5)

189

(17.6)

122

(13.6)

AJCC stage at diagnosis

           

   I

1,435

722

(31.3)

183

(21.7)

94

(19.4)

212

(19.8)

224

(24.9)

   II

2,425

956

(41.5)

365

(43.3)

199

(41.0)

541

(50.4)

364

(40.5)

   III

1,102

430

(18.6)

214

(25.4)

126

(26.0)

213

(19.9)

119

(13.3)

   IV

327

127

(5.5)

47

(5.6)

45

(9.3)

63

(5.9)

45

(5.0)

   Unstaged/NA

316

71

(3.1)

34

(4.0)

21

(4.3)

44

(4.1)

146

(16.3)

Grade

           

   Low

2,222

1,370

(59.4)

341

(40.5)

104

(21.4)

100

(9.3)

307

(34.2)

   High

3,022

849

(36.8)

466

(55.3)

356

(73.4)

939

(87.5)

412

(45.9)

   Unknown

361

87

(3.8)

36

(4.3)

25

(5.2)

34

(3.2)

179

(19.9)

Tumor size

           

   ≤2 cm

2,165

1,056

(45.8)

326

(38.9)

157

(32.4)

320

(29.8)

306

(34.0)

   > 2 cm

3,093

1,177

(51.0)

479

(57.1)

284

(58.6)

705

(65.7)

448

(49.8)

Microinvasion

56

15

(0.7)

7

(0.8)

8

(1.7)

b

 

26

(2.9)

   Diffuse

38

10

(0.4)

b

 

12

(2.5)

9

(0.8)

b

 

   Unknown

253

48

(2.1)

27

(3.2)

24

(5.0)

39

(3.6)

115

(12.8)

Lymph node involvement

           

   No

2,761

1,155

(50.1)

358

(42.5)

189

(39.0)

566

(52.8)

493

(54.9)

   Yes

2,707

1,123

(48.7)

472

(56.0)

286

(59.0)

491

(45.8)

335

(37.3)

   Unknown

137

28

(1.2)

13

(1.5)

10

(2.1)

16

(1.5)

70

(7.8)

Prior cancer

           

   First primary

5,226

2,169

(94.1)

796

(94.4)

459

(94.6)

993

(92.5)

832

(92.7)

   Non-first primary

379

137

(5.9)

47

(5.6)

26

(5.4)

80

(7.5)

66

(7.3)

  1. aHuman epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-). bStatistic not displayed because of five or fewer cases.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us